Lycia Therapeutics (LYCA) closed at $30.50 on November 6, 2026, up 5.9% from the previous close, on volume of 363,719 shares (30-day average 535,628).
Data as of November 6, 2026.
No headlines found.
Globe Newswire (Mon, 26-Oct 4:12 PM ET)
Lycia Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases.
Lycia Therapeutics trades on the NASDAQ stock market under the symbol LYCA.
As of November 6, 2026, LYCA stock price climbed to $30.50 with 363,719 million shares trading.
LYCA has a market cap of $1.59 billion. This is considered a Small Cap stock.
LYCA support price is $26.10 and resistance is $31.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LYCA shares will trade within this expected range on the day.
